| Identification | More | [Name]
Suplatast tosilate | [CAS]
94055-76-2 | [Synonyms]
(2-(4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl)ethyl)dimethylsulfonium p-toluenesulfonate
SUPLATAST TOSILATE
Suplatast tosylate
Suplatast
2-[4-(2-Hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethyldimethylsulfonium·4-methylbenzenesulfonate
IPD-1151T
S,S-Dimethyl-3-oxo-3-[4-(2-hydroxy-3-ethoxypropoxy)anilino]propane-1-sulfonium·4-methylbenzenesulfonate
[2-[[[4-(2-Hydroxy-3-ethoxypropoxy)phenyl]amino]carbonyl]ethyl]dimethylsulfonium
[2-[4-(2-Hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium
[3-Oxo-3-[4-(2-hydroxy-3-ethoxypropoxy)phenylamino]propyl]dimethylsulfonium
2-[4-(2-Hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethyldimethylsulfonium
N-[4-(2-Hydroxy-3-ethoxypropoxy)phenyl]-3-(dimethylsulfonio)propanamide | [Molecular Formula]
C23H33NO7S2 | [MDL Number]
MFCD00867604 | [Molecular Weight]
499.641 | [MOL File]
94055-76-2.mol |
| Chemical Properties | Back Directory | [Melting point ]
84-87°C | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMSO: >20mg/mL | [form ]
powder | [color ]
white to off-white | [Merck ]
14,9003 | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. | [CAS DataBase Reference]
94055-76-2(CAS DataBase Reference) |
| Safety Data | Back Directory | [WGK Germany ]
3 | [RTECS ]
WR7906000 | [HS Code ]
2930.90.2900 | [Toxicity]
LD50 in male, female mice, male, female rats (mg/kg): 81, 96, 96, 93 i.v.; in mice, rats (g/kg): >12.5, >10 orally (Yamashita) |
| Hazard Information | Back Directory | [Description]
Suplatast tosylate is a unique dimethylsulfonium salt marketed in Japan
for the treatment of bronchial asthma, atopic dermatitis and allergic rhinitis. Suplatast
tosylate is a potent inhibitor of IgE synthesis without suppressing IgM and IgG. The
mechanism of action for suplatast tosylate is thought to be via the inhibition of
interleukin-4 and interleukin-6 production by T-cells at the gene level. In allergic
patients, suplatast tosylate markedly improved clinical symptoms which correlated with
a significant decrease in serum IgE antibody levels. | [Originator]
Taiho (Japan) | [Uses]
Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM. | [Uses]
Suplatast Tosylate is an antiallergic drug. Suplatast Tosylate inhibits antigen-induced histamine release from mast cells as well as IgE antibody formation. Suplatast Tosylate suppresses interleukin (IL)-4 release from T cells, however in human peripheral basophils, Suplatast Tosylate inhibited the antigen-induced release of IL-13 but not IL-4. | [Brand name]
IPD | [Biological Activity]
Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN- γ production. Acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active. | [References]
1) Kurokawa?et al.?(2001),?Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo; Mediators Inflamm.,?10?333
2) Hsu?et al.?(2007),?The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells; Transpl. Immunol.,?18?108
3) Furonaka?et al.?(2009),?Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice; Curr. Opin. J. Pharmacol. Exp. Ther.,?328?55
4) Bhattachrya?et al.?(2014),?Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis; J. Biol. Chem.,?289?33404
5) Wada?et al.?(2009),?Effect of suplatast tosilate on antileukotriene non-responders with mild-to-moderate persistent asthma; Allergol. Int.,?58?389 |
|
|